Perrigo Co PLC

Latest Perrigo Co PLC News and Updates

  • uploads///Select Generic Pharma Companies Sales by Geo
    Healthcare

    What Are Biosimilars and Why Do They Benefit Generic Pharma?

    BUTCHER: Going back to what you said about generics being a cheaper alternative, why are they cheaper? DUFFY: The barriers to generic markets are usually a lot lower. If we look at the United States, back in 1984 they passed the Hatch-Waxman Act and essentially what this did was allow for an expedited approval process […]

    By VanEck
  • uploads///revenue ee
    Earnings Report

    How Did Valeant Fare in 2Q16?

    Valeant Pharmaceuticals (VRX) announced earnings for 2Q16 on August 9, 2016.

    By Jillian Dabney
  • uploads///PRGO
    Consumer

    Must-know: Davidson Kempner exits position in Perrigo

    Perrigo acquired Irish biotech company Elan last year for $8.6 billion.

    By Samantha Nielson
  • uploads///thermometer _
    Earnings Report

    Eli Lilly and Co.’s Strong Q1 Results, Updated 2018 Guidance

    Eli Lilly and Co. reported revenues of ~$5.7 billion for 1Q18 today, reflecting 9% growth from 1Q17.

    By Mike Benson
  • uploads///AAPLQ
    Technology & Communications

    Davidson Kempner Capital buys a new 4Q13 stake in Apple

    Davidson Kempner added a new position in Apple Inc. (AAPL) that accounted for 2.19% of the fund’s 4Q portfolio. Apple found favor with hedge funds last quarter.

    By Samantha Nielson
  • uploads///ANR
    Company & Industry Overviews

    What Do Analysts Recommend for Valeant after Recent Happenings

    The consensus 12-month target price for Valeant Pharmaceuticals is $36, which translates to a ~77.3% return potential compared to Valeant’s closing price of $20.3 on November 2, 2016.

    By Jillian Dabney
  • uploads///Chart  EPS
    Miscellaneous

    Understanding Allergan’s Valuation after the 1Q17 Results

    On May 10, 2017, Allergan (AGN) was trading at a forward PE multiple of ~14.1x, as compared to the industry average of 11.9x.

    By Mike Benson
  • uploads///Geographic exposure
    Company & Industry Overviews

    Central Nervous System Is Key to Teva’s Specialty Medicines

    Revenues for Teva’s (TEVA) Specialty Medicines segment grew by 2.1% to $8,560 million in 2014, from $8,388 million in 2013.

    By Nicole Sario
  • uploads///Graph
    Company & Industry Overviews

    Akorn’s Macro-Level Challenges in the Generic Drug Segment

    Although generic drugs only account for 3% of the total healthcare costs in the US, regulators continue to be concerned about rising generic pricing.

    By Margaret Patrick
  • uploads///Part
    Consumer

    David Einhorn Was Right about Apple

    Greenlight Capital (GLRE) exited its position in Apple in the third quarter of 2018.

    By Anuradha Garg
  • Consumer

    Why Bridgewater starts new position in Bed, Bath and Beyond

    Bridgewater Associates disclosed a new position in Bed, Bath & Beyond (BBBY). It accounted for 0.11% of the fund’s total portfolio.

    By Patricia Garner
  • uploads///csco
    Technology & Communications

    Why Bridgewater Associates decreased its position in Cisco

    Bridgewater Associates decreased its position in Cisco from 0.20% in the 1Q portfolio to 0.09% in the fund’s 2Q portfolio.

    By Patricia Garner
  • uploads///Chart
    Company & Industry Overviews

    What Are Pfizer’s Revenue Drivers?

    Pfizer reported revenues of $13.5 billion during the second quarter—4% growth YoY compared to $12.9 million during the second quarter of 2017.

    By Mike Benson
  • uploads///rawpixel  unsplash
    Company & Industry Overviews

    Analyzing Perrigo’s Spin-Off of Its Rx Business

    In this series, we’ll analyze major spin-offs in the healthcare sector by Perrigo (PRGO), Eli Lilly (LLY), Danaher (DHR), and Henry Schein.

    By Kenneth Smith
  • uploads///Chart
    Company & Industry Overviews

    How Eli Lilly’s Business Segments Performed in Q2 2018

    Eli Lilly and Company reports its business revenue under two segments: the Human Pharmaceutical segment and Elanco, the Animal Health segment.

    By Mike Benson
  • uploads///dna _
    Company & Industry Overviews

    Pfizer’s EC Approval of Xeljanz for Active Psoriatic Arthritis

    Pfizer (PFE) announced in a press release yesterday that the European Commission has approved its marketing authorization application for Xeljanz in combination with methotrexate for active psoriatic arthritis.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    These Pfizer Products Saw Declining Sales in 4Q17

    A few products in Pfizer’s (PFE) portfolio reported declining sales in 4Q17 following their loss of market share to the competition.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    GlaxoSmithKline Could Witness Modest Rise in Revenues in 2017

    GlaxoSmithKline (GSK) is a leading player in the global respiratory market with a major focus on the asthma and chronic obstructive pulmonary disease (or COPD) segments.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    What Analysts Recommend for GlaxoSmithKline in January 2018

    Of the 31 analysts covering GlaxoSmithKline in January 2018, five have recommended a “strong buy,” seven have recommended a “buy,” 15 have recommended a “hold,” three have recommended a “sell,” and only one has recommended a “strong sell.”

    By Margaret Patrick
  • uploads///Chart
    Earnings Report

    Pfizer: Revenue Growth Is Expected in 4Q17

    Wall Street analysts expect Pfizer’s (PFE) revenues to increase ~0.7% to $13.72 billion during 4Q17—compared to revenues of $13.63 billion during 4Q16.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Recent Developments for Mylan

    Recent developments reported by Mylan (MYL) include commercial developments as well as product developments. Let’s take a closer look.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Elagolix May Advance the Treatment Paradigm in Women’s Health

    On October 27, 2017, AbbVie (ABBV) announced that the New Drug Application for its investigational drug Elagolix had been granted priority review by the FDA.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Mylan’s Valuation in January 2018

    Mylan (MYL) is a leading pharmaceutical company with over 1,400 generic and specialty pharmaceutical products in its portfolio.

    By Mike Benson
  • uploads///Chart  Oncology
    Company & Industry Overviews

    Behind Eli Lilly’s Alimta and Other Oncology Products in 3Q17

    In 3Q17, Eli Lilly’s overall revenues from oncology products fell due to lower sales of Alimta, Erbitux, and Portrazza, offset by a rise in Cyramza sales.

    By Mike Benson
  • uploads///Chart
    Earnings Report

    Merck’s 3Q17 Revenues Could Rise

    Analysts expect Merck’s (MRK) revenues for 3Q17 to be around $10,546 million, nearly a 0.1% increase as compared to the revenues of $10,536 million reported for 3Q16.

    By Mike Benson
  • uploads///Chart  Keytruda
    Company & Industry Overviews

    Behind the Latest Developments for Merck’s Keytruda

    Keytruda (pembrolizumab) is a prescription medicine from Merck’s (MRK) immuno-oncology franchise used for the treatment of various tumors.

    By Mike Benson
  • uploads///Chart  Cardio
    Company & Industry Overviews

    Eli Lilly’s Cardiovascular Products in 2Q17

    Eli Lilly and Co.’s (LLY) cardiovascular franchise includes two drugs—Cialis and Effient. These drugs comprise ~15.0% of the company’s total revenues.

    By Mike Benson
  • uploads///Part  ALB
    Company & Industry Overviews

    Albemarle Appointed Laurie Brlas to Board of Directors

    For the week ended June 30, 2017, Albemarle (ALB) rose 0.7% and closed at $105.54.

    By Peter Neil
  • uploads///Graph
    Company & Industry Overviews

    Dupixent May Be a Major Growth Driver for Regeneron in 2017

    After Dupixent’s commercial launch, Regeneron has been involved in creating awareness for the drug among physicians who have been treating AD patients.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    Allergan’s Valuation Compared to Its Peers

    Allergan’s stock value fell more than 40% over the last 12 months. Analysts estimate that the stock could to return ~39.5% over the next 12 months.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Pfizer Has a Revenue-Boosting Treatment to Help Smokers Quit

    Approved by the FDA on May 11, 2006, Chantix, also known as Champix, is used as an aid to help cigarette smokers quit the habit of smoking.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Is Well Positioned for New Trends in the US Generic Market

    Because of its drug portfolio, manufacturing operations, and customer relationships, Teva expects to benefit from new trends in the US generic market.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva’s OTC Business Is Playing out to Be a Key Growth Driver

    In addition to its generic pharmaceutical business, Teva Pharmaceutical also has a significant presence in the major categories of the OTC drug business.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Akorn in 2016: What Are Its Key Risk Factors?

    In addition to industry-specific risks faced by all generic pharmaceutical players, Akorn (AKRX) faces certain company-specific risks.

    By Margaret Patrick
  • uploads///Chart
    Company & Industry Overviews

    How Did Bristol-Myers Squibb’s Eliquis Perform?

    Bristol-Myers Squibb’s (BMY) cardiovascular segment consists of its key drug Eliquis. This segment contributed nearly 78% of total revenues for 2Q16.

    By Mike Benson
  • uploads///Graph
    Company & Industry Overviews

    Teva Pharmaceutical: A Successful Bond Financing Program in 2016

    To finance the acquisition of Allergan Generics (AGN), Teva Pharmaceutical (TEVA) successfully completed a global bond offering on July 21, 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Teva Aims to Improve Its Position with Actavis Generics Acquisition

    Teva Pharmaceutical expects to benefit from improved productivity after the completion of the deal with Actavis Generics.

    By Margaret Patrick
  • uploads///Portfolio Breakdown of the TWCGX
    Company & Industry Overviews

    A Look at Portfolio Changes in TWCGX

    The American Century Growth Fund Investor Class (TWCGX) invests in companies that its managers believe will increase in value over time.

    By David Ashworth
  • uploads///Graph
    Company & Industry Overviews

    Consumer Healthcare Should Be a Key Driver of Perrigo’s 2016 Growth

    The Consumer Healthcare (or CHC) segment, a key part of Perrigo’s consumer business, is expected to account for about 45% of the company’s total revenues in 2016.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    Perrigo Leads the Over-the-Counter Store-Branded Products Market

    Perrigo is a market leader in over-the-counter store-branded products. Its leadership position extends to major geographies such as the US, the UK, and Mexico.

    By Margaret Patrick
  • uploads///Graph
    Company & Industry Overviews

    An Overview of Perrigo’s Business Model

    Perrigo’s business model includes a well-aligned organizational structure of its segments and a strong product portfolio.

    By Margaret Patrick
  • uploads///Article
    Company & Industry Overviews

    Nutritionals: Abbott Laboratories’ Main Segment

    Abbott Laboratories’ (ABT) nutritional products segment includes a broad line of pediatric and adult nutritional products manufactured and marketed worldwide.

    By Mike Benson
  • uploads///Margins
    Earnings Report

    Why Teva’s Generic Medicines Profitability Improved in 1Q15

    Teva’s increased profitability for its generic medicines was partially offset by decreased profitability of its specialty medicines, which were down by 13% in 1Q15 from 1Q14.

    By Nicole Sario
  • uploads///PRGO_Rx to OTC
    Miscellaneous

    Mylan–Perrigo Merger: Expanding into Over-the-Counter Drugs

    Pharmaceutical company Mylan’s (MYL) intention to acquire Perrigo became public on April 6, 2015. The acquisition would permit Mylan to expand into the over-the-counter drugs segment.

    By Nicole Sario
  • uploads///Value Chain
    Company & Industry Overviews

    Generics Are Climbing up the Value Chain

    Severe cost pressure can lead to the commoditization of generics. it’s important to adjust the value chain to achieve higher efficiencies, flexibility, and reliability.

    By Nicole Sario
  • uploads///Drug Market
    Company & Industry Overviews

    Are Generics the Only Affordable Drugs?

    Drugs are used to treat, cure, or prevent diseases. The drug market is broadly categorized into prescription drugs and OTC (over-the-counter) drugs.

    By Nicole Sario
  • uploads///Prescription Market
    Company & Industry Overviews

    What Investors Need to Know about Branded and Generic Drugs

    The prescription drug market is divided into two categories—branded or generic drugs. Branded drugs are patented drugs. Generics are off-patented drugs.

    By Nicole Sario
  • uploads///NEE
    Materials

    Millennium Management increases its stake in NextEra Energy

    Millennium Management increased its stake in renewable energy generator NextEra Energy Inc. (NEE) from 1,789,954 shares to 3,333,627 shares.

    By Samantha Nielson
  • uploads///PRGO
    Materials

    Israel Englander’s Millennium Management ups its stake in Perrigo

    Millennium Management ups position in Perrigo Company PLC (PRGO) that currently accounts for 1.28% of the fund’s 4Q portfolio.

    By Samantha Nielson
  • uploads///STI
    Materials

    Millennium Management buys a new position in SunTrust Banks

    Millennium Management started a new position in SunTrust Banks (STI) that accounts for 0.15% of the fund’s portfolio.

    By Samantha Nielson
  • © Copyright 2022 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.